Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma)

MLA

Johannes M. Waldschmidt, et al. “Safety and Efficacy of Vorinostat, Bortezomib, Doxorubicin and Dexamethasone in a Phase I/II Study for Relapsed or Refractory Multiple Myeloma (VERUMM Study: Vorinostat in Elderly, Relapsed and Unfit Multiple Myeloma).” Haematologica, vol. 103, no. 10, Oct. 2018. EBSCOhost, https://doi.org/10.3324/haematol.2018.189969.

APA

Johannes M. Waldschmidt, Alexander Keller, Gabriele Ihorst, Olga Grishina, Stefan Müller, Dagmar Wider, Anna V. Frey, Kristina King, Roman Simon, Annette May, Pierfrancesco Tassone, Justus Duyster, Manfred Jung, Noopur Raje, Ralph Wäsch, & Monika Engelhardt. (2018). Safety and efficacy of vorinostat, bortezomib, doxorubicin and dexamethasone in a phase I/II study for relapsed or refractory multiple myeloma (VERUMM study: vorinostat in elderly, relapsed and unfit multiple myeloma). Haematologica, 103(10). https://doi.org/10.3324/haematol.2018.189969

Chicago

Johannes M. Waldschmidt, Alexander Keller, Gabriele Ihorst, Olga Grishina, Stefan Müller, Dagmar Wider, Anna V. Frey, et al. 2018. “Safety and Efficacy of Vorinostat, Bortezomib, Doxorubicin and Dexamethasone in a Phase I/II Study for Relapsed or Refractory Multiple Myeloma (VERUMM Study: Vorinostat in Elderly, Relapsed and Unfit Multiple Myeloma).” Haematologica 103 (10). doi:10.3324/haematol.2018.189969.